Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. (FOLD) Stock Overview

Explore Amicus Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

FOLD●NASDAQ
HealthcareBiotechnology
$14.49
$0.00(0.00%)
U.S. Market is Open · 15:09

Amicus Therapeutics, Inc. (FOLD)

Meyka AI Score

Z

Key Financials

Market Cap4.5B
P/E Ratio-163.73
EPS (TTM)$-0.09
ROE-0.12%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 Months$19.37
1 Year Target$11.47

FOLD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Amicus Therapeutics, Inc. (NASDAQ: FOLD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Amicus Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of FOLD on the NASDAQ shows an RSI of 0.00, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $11.47 for the NASDAQ listing.

Key metrics behind Amicus Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -163.73 and a market capitalization of 4.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of FOLD on the NASDAQ.

Price Performance (NASDAQ: FOLD)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
0.84%
6-Month Change
45.92%
Year-to-Date (YTD) Change
1.76%
1-Year Change
132.21%
3-Year Change
29.49%
5-Year Change
61.00%
All-Time (Max) Change
0.42%

Contact Information

https://amicusrx.com
215 921 7600
3675 Market Street, Philadelphia, PA, 19104

Company Facts

4,990 Employees
IPO DateMay 31, 2007
CountryUS

Frequently Asked Questions